Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group

Update on the profile of the EUSTAR cohort: an analysis of the EULAR Scleroderma Trials and Research group database

(2012) Florian M P Meier et al.   ANNALS OF THE RHEUMATIC DISEASES

Two-year Results of an Open Pilot Study of a 2-treatment Course with Rituximab in Patients with Early Systemic Sclerosis with Diffuse Skin Involvement

(2012) V. SMITH et al.   JOURNAL OF RHEUMATOLOGY

Successful treatment of steroid and cyclophosphamide-resistant diffuse scleroderma-associated interstitial lung disease with rituximab

(2010) Wan-Hee Yoo   RHEUMATOLOGY INTERNATIONAL

B cell depletion in diffuse progressive systemic sclerosis: safety, skin score modification and IL-6 modulation in an up to thirty-six months follow-up open-label trial

(2010) Silvia Bosello et al.   ARTHRITIS RESEARCH & THERAPY

B cell depletion with rituximab in patients with diffuse cutaneous systemic sclerosis

(2009) Robert Lafyatis et al.   ARTHRITIS AND RHEUMATISM

CD20-depleting therapy in autoimmune diseases: from basic research to the clinic

(2009) F. Perosa et al.   JOURNAL OF INTERNAL MEDICINE

Experience with rituximab in scleroderma: results from a 1-year, proof-of-principle study

(2009) Dimitrios Daoussis et al.   RHEUMATOLOGY

Is There a Role for B-cell Depletion as Therapy for Scleroderma? A Case Report and Review of the Literature

(2009) Dimitrios Daoussis et al.   SEMINARS IN ARTHRITIS AND RHEUMATISM

Rituximab in diffuse cutaneous systemic sclerosis: an open-label clinical and histopathological study

(2008) V Smith et al.   ANNALS OF THE RHEUMATIC DISEASES

Skin involvement in systemic sclerosis

(2008) L. Czirjak et al.   RHEUMATOLOGY